Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
Clinical trial NCT04152863 · TERMINATED
Trial details
- NCT number
- NCT04152863
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-05
- Primary completion
- 2023-07-12
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.